The stock will cease trading following delisting, and FOLD shareholders have been paid out in full. No further corporate actions are expected as Amicus operates as a private subsidiary of BioMarin. Monitor BioMarin's financial reports for integration updates.
Price Chart
Executive Summary
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting from Nasdaq, and termination of its credit agreement. All directors and executive officers resigned, with BioMarin appointing new leadership. Shareholders received $14.50 per share in cash.
Key Facts
- Merger with BioMarin Pharmaceutical completed on April 27, 2026, with Amicus becoming a wholly owned subsidiary.
- Shareholders received $14.50 per share in cash as merger consideration.
- Company common stock to be delisted from Nasdaq; Form 25 filed for deregistration.
- All nine directors and five executive officers resigned; BioMarin appointees took over leadership roles.
- Amended and restated certificate of incorporation reduces authorized shares to 100 common shares.
- Credit agreement with Blackstone and Wilmington Trust terminated; all debt repaid.
Financial Impact
$14.50 per share cash payment to shareholders; full repayment of outstanding credit facility
Risk Factors
- Loss of public market liquidity for former shareholders
- Integration risks within BioMarin's organization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016968 |
| Document: ef20071351_8k.htm | 0001140361-26-016968 |
| Document: ef20071351_ex3-1.htm | 0001140361-26-016968 |
| Document: 0001140361-26-016968-index-headers.html | 0001140361-26-016968 |
| Document: 0001140361-26-016968-index.html | 0001140361-26-016968 |
| Document: 0001140361-26-016968.txt | 0001140361-26-016968 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 7, 2026 21w ago | 15-12G | — | awaiting T+1 | — | — |
Apr 27, 2026 22w ago | 8-K | $14.49 $14.49 | · 0.00% | ▲ +0.49% | — |
Apr 23, 2026 23w ago | 8-K | $14.49 $14.49 | · 0.00% | ▼ −0.16% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access